CD4 and neoplasm: In contrast, the efficacy of combined aCD40 and ICB treatment required both CD4 + and CD8 + T cells along with cDC1s for primary tumor rejection, highlighting the cooperative nature of these immune populations in mediating maximal therapeutic responses in the context of combination immunotherapy.